Pliant Therapeutics Inc is a biotechnology company focused on the development of innovative therapies for fibrotic diseases
The company is dedicated to discovering and advancing novel treatments that address the underlying mechanisms of tissue scarring and fibrosis across various organs. By leveraging its expertise in cellular and molecular biology, Pliant aims to transform the lives of patients suffering from debilitating conditions caused by excessive connective tissue growth, ultimately contributing to improved health outcomes and better quality of life.
Shares of Air Products and Chemicals, Inc. (NYSEAPD) fell sharply during Monday’s session after the company reported worse-than-expected first-quarter financial results and lowered FY24 adjusted EPS guidance below estimates.
Pliant Therapeutics reports 12-week interim data for bexotegrast in INTEGRIS-PSC Phase 2a trial. 320 mg group met primary and secondary endpoints, showing well-tolerance and reduction in liver fibrosis.
Keybanc cut the price target for Danaher Corporation (NYSEDHR) from $325 to $300. Keybanc analyst Paul Knight maintained an Overweight rating. Danaher shares rose 0.6% to $248.75 in pre-market trading.
Pliant Therapeutics Inc (NASDAQPLRX) announced data from the INTEGRIS-PSC Phase 2a trial of bexotegrast in patients with primary sclerosing cholangitis (PSC) and suspected
Gainers Soleno Therapeutics, Inc. (NASDAQSLNO) shares jumped 318.5% to $18.54 after the company released top-line results from randomized withdrawal period of study C602 of DCCR for Prader-Willi Syndrome.
Idiopathic Pulmonary Fibrosis (IPF) is a serious chronic lung disease characterized by the thickening and stiffening of the lung tissue surrounding the air sacs. The exact cause of IPF is unknown, but it is believed to involve a combination of genetic and environmental factors.
